Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06287138
Other study ID # KY2023-182-03
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 10, 2023
Est. completion date March 31, 2025

Study information

Verified date December 2023
Source Capital Medical University
Contact Jian-Xin Zhou, MD
Phone +8613801183875
Email zhoujx.cn@icloud.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Sedatives and analgesics are usually given for analgesic, anxiolytic, or sedating purposes for patients with critical illness, while they inevitably inhibit respiratory and circulatory function. Sometimes, patients receive deep sedation to induce hypoventilation or suppress spontaneous respiratory effort. The sedation level in clinical practice is usually assessed with subjective sedation scoring systems, such as the Richmond Agitation Sedation Scale (RASS). However, studies have found that sedation depth based on RASS is not a reliable marker of respiratory drive during critical illness. In recent years, researchers have proposed to monitor the effects of sedatives and analgesics on respiratory indicators and to implement lung-protective sedation, such as P0.1, Pocc, Pmus, WOB, and PTP. However, different pharmacological characteristics, different depths of sedation, and different sedation regimens among different sedatives and analgesics make a great difference in their effects on respiration. Ciprofol is an analog of propofol, with increased stereoselective effects adding to its anesthetic properties, is increasingly used in the intensive care unit, but its effects on respiration are not well understood. Therefore, this study aims to investigate the effects of ciprofol on respiratory patterns, respiratory drive, and inspiratory effort in mechanically ventilated patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date March 31, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - The patient received surgery under general anesthesia and admitted into the ICU - The patient has been intubated and is receiving invasively mechanically ventilated with the mode of pressure support (PSV) or continuous positive airway pressure (CPAP) - The patient requires sedative medication targeting RASS -2 to +1 for comfort, safety and to facilitate the delivery of life support measures Exclusion Criteria: - Age < 18 years - Body mass index (BMI) <18 or >30 kg/m2 - Pregnancy or lactation - Brain stem tumors, myasthenia gravis, or neuromuscular diseases - Acute severe neurological disorder and any other condition interfering with RASS assessment - Systolic blood pressure < 90 mmHg after appropriate intravenous volume replacement and continuous infusions of 2 vasopressors - Heart rate < 50 beats per minute or second- or third-degree heart block in the absence of a pacemaker - Contraindicate or allergic to any of the study medications - Acute hepatitis or serious hepatic dysfunction (Child-Pugh class C) - Chronic kidney disease with glomerular filtration rate (GFR) < 60 ml/min/1.73m2 - Alcohol abuse

Study Design


Intervention

Drug:
ciprofol
Ciprofol will be infused at 0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h in sequence for 30 minutes at each dose.

Locations

Country Name City State
China Beijing Tiantan Hospital Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Capital Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Explore the effect of ciprofol on tidal volume Change from baseline in tidal volume (ml) at 30 minutes after infusion of ciprofol At baseline (before sedation with ciprofol) and 0.3 mg/kg/h ciprofol continuous infusion for 30 minutes
Primary Explore the effect of ciprofol on respiratory rate Change from baseline in respiratory rate (breaths/min) at 30 minutes after infusion of ciprofol At baseline (before sedation with ciprofol) and 0.3 mg/kg/h ciprofol continuous infusion for 30 minutes
Primary Explore the effect of ciprofol on minute ventilation Change from baseline in minute ventilation (L/min) at 30 minutes after infusion of ciprofol At baseline (before sedation with ciprofol) and 0.3 mg/kg/h ciprofol continuous infusion for 30 minutes
Primary Explore the effect of ciprofol on P0.1 Change from baseline in P0.1 (cmH2O) at 30 minutes after infusion of ciprofol At baseline (before sedation with ciprofol) and 0.3 mg/kg/h ciprofol continuous infusion for 30 minutes
Primary Explore the effect of ciprofol on PMI Change from baseline in PMI (cmH2O) at 30 minutes after infusion of ciprofol At baseline (before sedation with ciprofol) and 0.3 mg/kg/h ciprofol continuous infusion for 30 minutes
Primary Explore the effect of ciprofol on ?Pocc Change from baseline in ?Pocc (cmH2O) at 30 minutes after infusion of ciprofol At baseline (before sedation with ciprofol) and 0.3 mg/kg/h ciprofol continuous infusion for 30 minutes
Secondary Explore the effect of ciprofol on tidal volume Change from baseline in tidal volume (ml) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on respiratory rate Change from baseline in respiratory rate (breaths/min) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on minute ventilation Change from baseline in minute ventilation (L/min) at 30 minutes after infusion of ciprofol at different infusion rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on P0.1 Change from baseline in P0.1 (cmH2O) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on PMI Change from baseline in PMI (cmH2O) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on ?Pocc Change from baseline in ?Pocc (cmH2O) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on systolic blood pressure Change from baseline in systolic blood pressure (mmHg) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on diastolic blood pressure Change from baseline in diastolic pressure (mmHg) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on mean arterial pressure Change from baseline in mean arterial pressure (mmHg) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on heart rate Change from baseline in heart rate (beats/min) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on saturation of pulse oxygen Change from baseline in saturation of pulse oxygen (%) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on end-tidal carbon dioxide pressure Change from baseline in end-tidal carbon dioxide pressure (mmHg) at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
Secondary Explore the effect of ciprofol on RASS score Change from baseline in RASS score at 30 minutes after infusion of ciprofol at different rates At baseline (before sedation with ciprofol) and 30 minutes following each infusion rate adjustment (0.3,0.4,0.5,0.6,0.7,0.8 mg/kg/h)
See also
  Status Clinical Trial Phase
Completed NCT05921656 - Construction and Evaluation of Airway Leakage Risk Model of Patients With Endotracheal Tube
Recruiting NCT03941002 - Continuous Evaluation of Diaphragm Function N/A
Withdrawn NCT04288076 - The Brain and Lung Interaction (BALI) Study N/A
Completed NCT03031860 - Semi-quantitative Cough Strength Score (SCSS) N/A
Completed NCT02312869 - Local Assessment of Management of Burn Patients N/A
Completed NCT02545621 - A Role for RAGE/TXNIP/Inflammasome Axis in Alveolar Macrophage Activation During ARDS (RIAMA): a Proof-of-concept Clinical Study
Completed NCT01885442 - TryCYCLE: A Pilot Study of Early In-bed Leg Cycle Ergometry in Mechanically Ventilated Patients N/A
Completed NCT01204281 - Proportional Assist Ventilation (PAV) in Early Stage of Critically Ill Patients Phase 4
Terminated NCT01059929 - Dexmedetomidine Versus Propofol in the Medical Intensive Care Unit (MICU) Phase 4
Completed NCT00824239 - Intermittent Sedation Versus Daily Interruption of Sedation in Mechanically Ventilated Patients Phase 3
Completed NCT00529347 - Mechanical Ventilation Controlled by the Electrical Activity of the Patient's Diaphragm - Effects of Changes in Ventilator Parameters on Breathing Pattern Phase 1
Unknown status NCT00260676 - Protective Ventilatory Strategy in Potential Organ Donors Phase 3
Terminated NCT00205517 - Sedation and Psychopharmacology in Critical Care N/A
Completed NCT03281785 - Ultrasound of Diaphragmatic Musculature in Mechanically Ventilated Patients. N/A
Recruiting NCT04110613 - RCT: Early Feeding After PEG Placement N/A
Completed NCT04410783 - The Emergency Department Sedation Pilot Trial N/A
Recruiting NCT04821453 - NAVA vs. CMV Crossover in Severe BPD N/A
Completed NCT03930147 - Ventilation With ASV Mode in Children N/A
Recruiting NCT05029167 - REstrictive Versus LIberal Oxygen Strategy and Its Effect on Pulmonary Hypertension After Out-of-hospital Cardiac Arrest (RELIEPH-study) N/A
Recruiting NCT04849039 - Lung Microbiota and VAP Development (PULMIVAP)